PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Investing in Inhalation Innovation: A funding guide for respiratory start-ups

At a time of geopolitical unrest, market unease and investment uncertainty, understanding and sourcing the right finance to move your respiratory technology from bench to market can feel daunting. Whether you are developing a novel inhaled therapy, a smarter dry powder inhaler or a connected nebulizer, the question is the same: which money, when, and at what cost?

As we look forward to our novel DDL Incubator titled ‘Investing in Inhalation Innovation’, we review the challenges, considerations and opportunities associated with each funding route.

The current funding climate

The good news is that respiratory innovators can still raise capital. The particular challenge we face today is that the funding environment is more selective, more concentrated and more politically uncertain than it was a few years ago, and that makes access uneven, especially for earlier-stage projects or startups.

Macro headwinds

Economic volatility and higher interest rates through 2025 made investors more cautious about long duration, high risk assets such as lifesciences R&D. Fundraising cycles lengthened and some planned rounds were derailed. Even though overall biotech financing was relatively strong in dollar terms, capital has not flowed evenly, indeed commentators refer to tightened financing and liquidity traps.

A narrowing IPO window

US biotech IPO activity dropped sharply in 2025, with only a handful of companies raising more than $50 million. In the UK and Europe, public markets are an even clearer weak spot, with reports of three consecutive years without a UK biotech IPO. That means specifically for UK respiratory start-ups, you cannot count on a listing to refinance your pipeline, you need to stretch private capital further and think creatively about structure. Meanwhile biotech IPO activity across the APAC region has experienced a notable rebound, driven heavily by Hong Kong’s market leadership. This rebound is characterised by a strong first half of the year, followed by an environment where investors are increasingly selective.

The rising gap between ‘haves and have nots’

Capital is concentrating into fewer, larger mega rounds for later stage, clinically validated assets, which is resulting in a widening gap between those and early and mid-stage companies. Those companies or projects with strong validation still attract oversubscribed rounds while less proven platforms can struggle to secure any institutional funding at all.

Policy uncertainty and competition for capital

Proposed cuts to FDA budgets and, therefore staff, and contentious drug-pricing initiatives, are cited as major obstacles to financing confidence. Meanwhile, the industry is also competing with artificial intelligence, which absorbed an estimated 80% of global venture capital in just one quarter recently. Add to that the reductions in public research funding, and fundraising is becoming a fulltime job for founders, with investors wanting more third-party validation before they commit.

Your funding options at a glance

The table below, kindly supplied by one of our speakers, Chris Hall of Shallcross Partners, provides a practical overview of the funding options. In our Hub we will discuss in more detail those options highlighted in bold.

Funding routeWhat it isPositivesNegatives
BootstrappingSelf-funding through personal resources or early revenueFull control; no dilution; fast decisionsLimited capital; personal financial risk; slower scaling
Friends & familyEarly money from personal contactsQuick access; flexible terms; early validationRelationship risk; limited strategic input
Grants & public fundingNon-dilutive funding from public or institutional bodiesNon-dilutive; credibility; supports R&DSlow processes; reporting and admin burden
Angel investorsIndividuals backing early-stage companies with capital and adviceMentorship; networks; early-stage expertiseEquity dilution; investor quality varies
Seed funds & venture capitalProfessional investors funding high-growth start-ups for equityLarge capital; scale quickly; strong signallingSignificant dilution; growth pressure; reduced control
Accelerators & incubatorsStructured programmes offering mentorship and small funding for equityMentorship; investor access; credibilityEquity for small capital; time-intensive
Revenue-based financingNon-equity funding repaid as a percentage of revenueNo dilution; repayments scale with revenueRequires revenue; cash-flow impact
Debt / loansBorrowed capital repaid with interestNo equity loss; predictable costRepayment risk; personal guarantees often required
Corporate / strategic investmentInvestment from established companies seeking strategic alignmentMarket access; industry knowledge; partnershipsStrategic constraints; slower decisions
CrowdfundingRaising from many individuals via online platformsValidation; marketing exposure; communityAdmin complexity; disclosure risk; investor management

The five routes to focus on

Bootstrapping: buy time and keep control

Bootstrapping means growing the business with personal savings, consulting income and early revenue. It keeps you in full control, but capital is limited and scaling is slow. Many companies bootstrap in a broader sense, stitching together grants, small contracts and shared lab or incubator space to delay dilution. This works best when burn is low, such as a virtual model using CROs, or a narrow device or diagnostic proof-of-concept.

Grants: de-risk the science without giving away equity

Grants don’t need repaying and don’t usually cost equity. The trade-off is slow processes, deliverables, audits and reporting, so you need clear workplans and endpoints. Used well, grants validate your science and de-risk early milestones before a larger equity round.

Angel investors: smart money at the early stage

Angels and family offices, often experienced entrepreneurs or industry executives, bring capital plus networks and domain expertise. For respiratory founders, an angel with inhalation, device or regulatory experience can be worth far more than the cheque. The caveats: you give away equity, and investor quality varies, so choose carefully!

Seed and venture capital: fuel to scale

VC is typically the main source of scale capital once initial technical risk is mitigated, and you need to fund preclinical packages, clinical trials and manufacturing. It offers large sums and strong market signalling, but it is expensive: significant dilution, board oversight, milestone pressure and an expectation of a high value exit. And timing really matters, raising after grants and early data have cleared key inflection points that means a higher valuation and stronger negotiating position.

Corporate and strategic investment: capital plus muscle

Pharma and device companies invest through corporate venture arms, option-to-license and co-development deals, sponsored research and early distribution agreements. For inhalation innovators, a strategic partner can bring formulation, device, regulatory and manufacturing capability that would be costly to build alone. The downside is strategic constraint, slower decisions and careful management of IP and exclusivity.

The typical funding journey

Funding routes are rarely chosen once – they stack up over time. A typical path looks like this:

StageMain investor typeTypical raise
Idea / prototypeBootstrapping£0–30k
MVP and tractionFriends & family£30–100k
Early growthGrants + angels£100–250k
Scale-upSeed / Series A VC£250k–£1m
ExpansionSeries B+ / strategic£1m+

As you progress your journey, founder ownership can fall from 100% to as little as 10%. That’s why two questions matter at every stage. First, how can you minimise development and scale-up costs while maximising income, to reduce the need for external funding? And second, what do you need to be credible to move to the next step?

What ‘investor ready’ really means

Investor readiness isn’t just having a deck and a good idea. It means your company can withstand professional scrutiny and justify the capital it is asking for, which in practice means fulfilling the following criteria…

  • Science and IP de-risking: robust data, not just hypotheses, plus a clear IP and freedom-to-operate position.
  • A value inflection map: milestones such as proof-of-concept, safety packages, device verification and clinical readouts, with each injection of capital tied to a point where risk drops and value rises.
  • A coherent narrative: connecting unmet respiratory need, your solution, the competitive landscape, the regulatory path and commercial potential.
  • Structured operations and governance: a functioning team with defined roles, ready for board oversight and reporting.
  • Financial clarity: a realistic burn rate, use of funds, timelines and valuation logic, including dilution and cap table.
  • External validation: grants won, accelerator places, KOL support and early partnerships, in other words evidence that others have already tested your claims

The bottom line

The funding environment is tougher than it has been for a while, but it isn’t closed. Respiratory start-ups that combine the right routes in the right order: bootstrapping and grants to prove the science, angels to build momentum, VC to scale and strategic partners to reach patients, will be best placed to secure the capital they need. Start with credibility, protect your equity for as long as you can, and make every raise count.

Want to know more? Join us at our Incubator Hub @DDL 2026. You can register here: https://ddl-conference.com/the-ddl-incubator/

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026